X4 PHARMACEUTICALS, INC Other Comprehensive Income (Loss), Net of Tax
X4 PHARMACEUTICALS, INC (XFOR) reported Other Comprehensive Income (Loss), Net of Tax of -$16.16 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTax · last filed 2026-08-06
- X4 PHARMACEUTICALS, INC other comprehensive income (loss), net of tax for the quarter ending 2026-06-30 was -$16.16M.
- X4 PHARMACEUTICALS, INC other comprehensive income (loss), net of tax for the quarter ending 2026-03-31 was -$20.25M, a 7438.41% decline year-over-year.
- X4 PHARMACEUTICALS, INC other comprehensive income (loss), net of tax for the quarter ending 2025-12-31 was -$23.92M.
- X4 PHARMACEUTICALS, INC other comprehensive income (loss), net of tax for the quarter ending 2025-09-30 was -$29.80M.
- X4 PHARMACEUTICALS, INC other comprehensive income (loss), net of tax for fiscal 2025 was -$79.19M.
- X4 PHARMACEUTICALS, INC other comprehensive income (loss), net of tax for fiscal 2024 was -$37.45M.
- X4 PHARMACEUTICALS, INC other comprehensive income (loss), net of tax for fiscal 2023 was -$101.17M.
| Period end | Other Comprehensive Income (Loss), Net of Tax 3 month | Other Comprehensive Income (Loss), Net of Tax 6 month | Other Comprehensive Income (Loss), Net of Tax 9 month | Other Comprehensive Income (Loss), Net of Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$16.16M 10-Q · filed 2026-08-06 | -$36.41M 10-Q · filed 2026-08-06 | -$60.33M derived: sum of 3 quarters · filed 2026-08-06 | -$90.12M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$20.25M 10-Q · filed 2026-05-06 | -$44.17M derived: sum of 2 quarters · filed 2026-05-06 | -$73.97M derived: sum of 3 quarters · filed 2026-05-06 | -$99.72M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$23.92M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | -$53.71M derived: sum of 2 quarters · filed 2026-03-17 | -$79.46M derived: sum of 3 quarters · filed 2026-08-06 | -$79.19M 10-K · filed 2026-03-17 |
| 2025-09-30 | -$29.80M 10-Q · filed 2025-11-05 | -$55.55M derived: sum of 2 quarters · filed 2026-08-06 | -$55.27M 10-Q · filed 2025-11-05 | -$95.10M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$25.75M 10-Q · filed 2026-08-06 | -$25.48M 10-Q · filed 2026-08-06 | -$65.30M derived: sum of 3 quarters · filed 2026-08-06 | -$101.95M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $276.00K 10-Q · filed 2026-05-06 | -$39.55M derived: sum of 2 quarters · filed 2026-05-06 | -$76.20M derived: sum of 3 quarters · filed 2026-05-06 | $14.62M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | -$39.83M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | -$76.48M derived: sum of 2 quarters · filed 2026-03-17 | $14.35M derived: sum of 3 quarters · filed 2026-03-17 | -$37.45M 10-K · filed 2026-03-17 |
| 2024-09-30 | -$36.65M 10-Q · filed 2025-11-05 | $54.18M derived: sum of 2 quarters · filed 2025-11-05 | $2.38M 10-Q · filed 2025-11-05 | -$16.76M derived: sum of 4 quarters · filed 2026-03-17 |
| 2024-06-30 | $90.83M 10-Q · filed 2025-08-08 | $39.02M 10-Q · filed 2025-08-08 | $19.89M derived: sum of 3 quarters · filed 2026-03-17 | $17.59M derived: sum of 4 quarters · filed 2026-03-17 |
| 2024-03-31 | -$51.80M 10-Q · filed 2025-05-01 | -$70.93M derived: sum of 2 quarters · filed 2026-03-17 | -$73.24M derived: sum of 3 quarters · filed 2026-03-17 | -$128.95M derived: sum of 4 quarters · filed 2026-03-17 |
| 2023-12-31 | -$19.13M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | -$21.43M derived: sum of 2 quarters · filed 2026-03-17 | -$77.15M derived: sum of 3 quarters · filed 2026-03-17 | -$101.17M 10-K · filed 2026-03-17 |
| 2023-09-30 | -$2.31M 10-Q · filed 2024-11-13 | -$58.02M derived: sum of 2 quarters · filed 2024-11-13 | -$82.04M 10-Q · filed 2024-11-13 | |
| 2023-06-30 | -$55.71M 10-Q · filed 2024-08-08 | -$79.73M 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | -$24.02M 10-Q · filed 2024-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |